Lanzul

Lansoprazole, the active ingredient in Lanzul, is a proton pump inhibitor presented as a tablet for oral use. It reduces gastric acid production and is prescribed for conditions such as gastro‑esophageal reflux disease, erosive esophagitis, peptic ulcer disease, and Helicobacter pylori eradication therapy.

GNH USA supplies Lanzul as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and providing reliable global distribution.

Lansoprazole is a proton pump inhibitor used to manage acid‑related gastrointestinal disorders. - Gastro‑esophageal reflux disease (GERD): alleviates heartburn and regurgitation by reducing acid exposure in the esophagus. - Erosive esophagitis: promotes healing of acid‑induced esophageal lesions. - Peptic ulcer disease: supports ulcer healing and prevents recurrence by maintaining low gastric acidity. - Helicobacter pylori eradication therapy: enhances the effectiveness of antibiotic regimens by suppressing gastric acid.

Lansoprazole may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: loose stools, often transient. - Nausea: feeling of stomach upset. - Abdominal pain: discomfort in the upper abdomen. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis presenting with watery diarrhea. - Acute interstitial nephritis: renal inflammation causing reduced urine output. - Hypomagnesemia: low serum magnesium leading to muscle cramps or arrhythmia. - Stevens‑Johnson syndrome: severe skin and mucous membrane reaction. - Fracture risk: increased incidence of hip, wrist, or spine fractures with long‑term use.

Before initiating lansoprazole therapy, consider the following precautions and safety measures. - Assess renal function: dose adjustment may be needed in severe impairment. - Evaluate hepatic status: use with caution in patients with liver disease. - Review long‑term use: prolonged therapy may increase risk of bone fractures and vitamin B12 deficiency. - Monitor electrolytes: especially magnesium and potassium during extended treatment. - Consider infection risk: gastric acid suppression can predispose to gastrointestinal infections. - Store at room temperature: keep below 25 °C, retain in original container, protect from moisture and light.

Lansoprazole can affect the plasma concentrations of several concomitant medicines; interactions are grouped by clinical significance.

Major Interactions (Avoid): - Antifungal agents (ketoconazole, itraconazole): reduced absorption and efficacy. - HIV protease inhibitors (atazanavir, nelfinavir): decreased serum levels. - Clopidogrel: diminished antiplatelet effect leading to reduced cardioprotection. - Warfarin: potential increase in INR and bleeding risk. - Methotrexate (high dose): increased toxicity due to reduced renal clearance.

Moderate Interactions (Monitor Closely): - Digoxin: possible increase in serum concentration. - Diazepam: enhanced sedative effect. - Iron salts: decreased iron absorption. - Vitamin B12 supplements: may require monitoring due to altered absorption. - Mycophenolate mofetil: modest increase in exposure.